Document is current
Any future updates will be listed below
-
Authors
Cappellari, Manuel https://orcid.org/0000-0002-3534-3201
Pracucci, Giovanni
Saia, Valentina
Fainardi, Enrico
Casetta, Ilaria
Sallustio, Fabrizio
Ruggiero, Maria
Longoni, Marco
Simonetti, Luigi
Zini, Andrea
Lazzarotti, Guido Andrea
Giannini, Nicola
Da Ros, Valerio
Diomedi, Marina
Vallone, Stefano
Bigliardi, Guido
Limbucci, Nicola
Nencini, Patrizia
Ajello, Daniele
Marcheselli, Simona
Burdi, Nicola
Boero, Giovanni
Bracco, Sandra
Tassi, Rossana
Boghi, Andrea
Naldi, Andrea
Biraschi, Francesco
Nicolini, Ettore
Castellan, Lucio
Del Sette, Massimo
Allegretti, Luca
Sugo, Annalisa
Buonomo, Orazio
Dell’Aera, Cristina
Saletti, Andrea
De Vito, Alessandro
Lafe, Elvis
Mazzacane, Federico
Bergui, Mauro
Cerrato, Paolo
Feraco, Paola
Piffer, Silvio
Augelli, Raffaele
Vit, Federica
Gasparotti, Roberto
Magoni, Mauro
Comelli, Simone
Melis, Maurizio
Menozzi, Roberto
Scoditti, Umberto
Cavasin, Nicola
Critelli, Adriana
Causin, Francesco
Baracchini, Claudio
Guzzardi, Giuseppe
Tarletti, Roberto
Filauri, Pietro
Orlandi, Berardino
Giorgianni, Andrea
Cariddi, Lucia Princiotta
Piano, Mariangela
Motto, Cristina
Gallesio, Ivan
Sepe, Federica Nicoletta
Romano, Giuseppe
Grasso, Maria Federico
Pauciulo, Alfredo
Rizzo, Annalisa
Comai, Alessio
Franchini, Enrica
Sicurella, Luigi
Galvano, Gianluca
Mannino, Marina
Mangiafico, Salvatore
Toni, Danilo
on behalf of the IRETAS group,
- License Information
-
More Information
Article History
Received: 10 January 2023
Accepted: 4 July 2023
First Online: 17 July 2023
Declarations
:
: The present study was in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Informed consent to use anonymized and aggregated data for participation in the studies including stroke patients treated with acute revascularization treatments was obtained in all patients of each center.
: MC: consultancy or advisory board fees or speaker’s honoraria from Boehringer Ingelheim, Pfizer/Bristol Meyer Squibb, and Daiichi Sankyo. MS: consultancy fees from Proctorship for Medtronic. AS: consultancy fees from Stryker. MB: consultation fees from Stryker, Penumbra. AZ: speaker fees and consulting fees from Boehringer Ingelheim, Medtronic, Cerenovus, and advisory board from Daiichi Sankyo and Boehringer Ingelheim and Stryker. ADV: consultancy fees from Boehringer Ingelheim and Daiichi Sankyo. All other authors report no conflicts of interest.
